The Global Health Body Issues Alert Over Critical Lack of Obesity Medications

Under a tenth of people eligible to benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it releases its inaugural advice on the drugs.

With more than one billion individuals worldwide now classified as obese, it is calling for broader and more equitable availability to these injectable treatments.

Per projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"The new guidelines affirms that excess weight is a long-term condition that can be addressed with holistic and continuous support," stated its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are key barriers to broad availability to the injections that can assist patients in reducing considerable weight, explains the body.

Skinny Jab Supply Crisis

Despite the current most optimistic scenario, the production of such drugs could only cover about 100 million people – less than 10% of those who need them, as stated by the health organization.

The advice encourages governments and firms to increase access, through measures like patent sharing.

Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in a number of countries in 2026.

The Way Obesity Jabs Operate

GLP-1 drugs mimick a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so individuals reduce food intake.

Patients commonly start to lose weight within a few weeks of commencing the regular doses.

Research suggests patients may regain a significant portion within a year of halting the medication, as their usual food cravings resume.

Being overweight or obese raises your risk for experiencing diseases, like type 2 diabetes, heart disease, brain attack, and certain malignancies.

Excess weight affects people in countries worldwide and was associated with millions of fatalities worldwide in 2024, according to the health agency.